New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
08:06 EDTRTRXRetrophin completes acquisition of Manchester Pharmaceuticals
Retrophin announced the completion of the previously announced acquisition of Manchester Pharmaceuticals LLC for a total of $62.5M, including an upfront payment of $29.5M, plus other payments based on product sales. Retrophin intends to pursue U.S. regulatory approval for Chenodal in cerebrotendinous xanthomatosis.
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2015
09:12 EDTRTRXRetrophin management to meet with Leerink
Subscribe for More Information
November 16, 2015
08:09 EDTRTRXRetrophin receives EU ODD for sparsentan
Retrophin announced that the European Commission, or EC, has granted sparsentan orphan drug designation for the treatment of focal segmental glomerulosclerosis, or FSGS. Retrophin previously announced in January 2015 that sparsentan received orphan drug designation from the FDA for the treatment of FSGS. Sparsentan is the company's investigational therapeutic agent which acts as both a potent angiotensin receptor blocker, as well as a selective endothelin receptor antagonist, and is currently being evaluated in the Phase 2 DUET trial in FSGS patients. FSGS is a widely recognized cause of end-stage renal disease and there are no approved pharmacologic treatments currently available in the United States or Europe.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use